Drugs Made In America Acquisition II Corp.
DMII
$9.96
$0.020.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 308.14% | -35.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 308.14% | -35.75% | |||
| Operating Income | -308.14% | 35.75% | |||
| Income Before Tax | -21.26% | 35.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.26% | 35.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.26% | 35.75% | |||
| EBIT | -308.14% | 35.75% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 73.08% | 36.59% | |||
| Normalized Basic EPS | 76.47% | 34.62% | |||
| EPS Diluted | 73.08% | 36.59% | |||
| Normalized Diluted EPS | 76.47% | 34.62% | |||
| Average Basic Shares Outstanding | 356.17% | 0.00% | |||
| Average Diluted Shares Outstanding | 356.17% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||